Larta wins NIH renew partnership to accelerate commercialization of SBIR/STTR technologies
Larta selected to continue to manage the agency's Commercialization Assistance Program for its Phase II SBIR/STTR grantees. This is a five-year contract from the National Institutes of Health (NIH) to develop and manage a commercialization assistance program for its NIH Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) Phase II awardees to accelerate the transition of the NIH-funded technologies into the marketplace. This is the third contract won by Larta since the onset of the program in 2004. We have collectively assisted 750+ companies over Larta’s experience in managing the NIH Commercialization Assistance Program, or "NIH CAP". The purpose of the NIH CAP is to provide eligible participants, all grantees of NIH's Phase II SBIR awards ith individualized assistance focused on strategic business planning, identifying and understanding their customers, developing materials appropriate to their commercialization efforts, and working towards establishing strategic partners and investors, as appropriate.
The program supports companies across various topic areas, including biotechnology, pharmaceuticals, medical devices, healthcare IT, diagnostics, research tools, and others.